Serum sickness-like reactions in patients receiving intravenous infliximab

Journal of Emergency Medicine

Volumn 30, Issue 1, 2006, Pages 41-44

  Gamarra, Roberto M ^a,b   McGraw, Steven D ^a   Drelichman, Vilma S ^a   Maas, Luis C ^a  

^a PROVIDENCE HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Delayed hypersensitivity; Drug reactions; Infliximab; Monoclonal antibodies; Serum sickness

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; INFLIXIMAB;

ADULT; ARTHRALGIA; ARTICLE; BONE PAIN; CASE REPORT; CHILL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; HEMATURIA; HUMAN; ILEITIS; LEUKOCYTOSIS; MALAISE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RASH; RECTOVAGINAL FISTULA; SEPSIS; SERUM SICKNESS; THORAX PAIN; TREATMENT OUTCOME; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; SERUM SICKNESS;

EID: 31144468334     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2005.01.033     Document Type: Article

References (27)

1. W.J. Sandborn, S.B. Hanauer Infliximab in the treatment of Crohn's disease a user's guide for clinicians Am J Gastroenterol 97 2002 2962 2972
2. M.A. Fitzcharles, D. Clayton, H.A. Menard The use of Infliximab in academic rheumatology practice an audit of early clinical experience J Rheumatol 29 2002 2525 2530
3. P.E. Lipsky, D.M.F.M. van der Heijde, E.W. St. Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden Infliximab and methotrexate in the treatment of RA N Engl J Med 343 2000 1594 1602
4. R.N. Maini, F.C. Breedveld, J.R. Kalden Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor (alpha) monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
5. M.J. Elliott, R.N. Maini, M. Feldmann Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
6. M.J. Elliott, R.N. Maini, M. Feldmann Repeated therapy with monoclonal antibody to tumor necrosis factor-alpha (cA2) in patients with rheumatoid arthritis Lancet 344 1994 1125 1127
7. S.R. Targan, S.R. Hanauer, S.J.H. van Deventer A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor (alpha) for Crohn's disease N Engl J Med 337 1997 1029 1035
8. S.B. Hanauer, B.G. Fegan, G.R. Lichtenstein Maintenance infliximab for Crohn's disease the ACCENT I randomized trial Lancet 359 2002 1541 1549
9. D.H. Present, P. Rutgeerts, S. Targan Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
10. P. Lipsky, W. St. Clair, D. Furst 54-week clinical and radiographic results from the ATTRACT trial a phase III study of infliximab (Rimicade) in patients with active RA despite methotrexate (abstract) Arthritis Rheum 42 Suppl 1999 S1980
11. M.J. Elliott, R.N. Maini, M. Feldmann Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-alpha Arthritis Rheum 36 1993 1681 1690
12. Remicade (infliximab) for IV injection. Package insert 2002 Centocor, Inc Malvern, PA
13. The diagnosis and management of anaphylaxis. Joint Task force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology J Allergy Clin Immunol 101 1998 S465 S528
14. C. Antoni, C. Dechant, H. Lorenz Successful treatment of severe psoriatic arthritis with infliximab (abstract) Arthritis Rheum 42 Suppl 1999 S1801
15. J. Braun, J. Brandt, J. Listing Treatment of active ankylosing spondylitis with infliximab a randomised controlled multicentre trial Lancet 359 2000 1187 1193
16. R. Jackson Serum sickness J Cutan Med Surg 4 2000 223 225
17. J.E. Erffmeyer Serum sickness Ann Allergy 56 1986 105 109
18. R. Platt, M.W. Dreis, D.L. Kennedy, J.N. Kuritsky Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim- sulfamethoxazole J Infect Dis 158 1988 474 477
19. S.B. Hanauer, P. Rutgeerts, S. Targan Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment (abstract) Gastroenterology 116 1999 A731
20. C.A. D'Arcy, M. Mannik Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab) Arthritis Rheum 44 2001 1717 1718
21. American Thoracic Society, Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection Am J Respir Crit Care Med 161 2000 S221 S247
22. B. Bresnihan, G. Cunnane Infection complications associated with the use of biologic agents Rheum Dis Clin North Am 29 2003 185 202
23. M.A. Gardam, E.C. Keystone, R. Menzies Anti-tumour necrosis factor agents and tuberculosis risk mechanisms of action and clinical management Lancet Infect Dis 3 2003 270 271
24. K.L. Wood, C.A. Hage, K.S. Knox Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy Am J Respir Crit Care Med 167 2003 1279 1282
25. M. Debandt, O. Vittecoq, V. Descamps, X. Le Loet, O. Meyer Anti-TNF-alpha-induced systemic lupus syndrome Clin Rheumatol 22 2003 56 61
26. E.G. Favalli, L. Sinigaglia, M. Varenna, C. Arnoldi Drug-induced lupus following treatment with infliximab in rheumatoid arthritis Lupus 11 2002 753 755
27. F. de' Clari, I. Salani, E. Safwan, A. Giannacco Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation 105 2002 E183